APOBEC3A catalyzes mutation and drives carcinogenesis in vivo

Emily K. Law(University of Minnesota), Rena Levin-Klein(University of Minnesota), Matthew C. Jarvis(University of Minnesota), Hyoung Kim(University of Pennsylvania), Prokopios P. Argyris(University of Minnesota), Michael A. Carpenter(University of Minnesota), Gabriel J. Starrett(National Institutes of Health), Nuri A. Temiz(University of Minnesota), Lindsay K. Larson(University of Minnesota), Cameron Durfee(University of Minnesota), Michael B. Burns(University of Minnesota), Rachel I. Vogel(University of Minnesota), Spyridon Stavrou(University of Illinois Chicago), Alexya N. Aguilera(University of Illinois Chicago), Sandra Wagner(University of Minnesota), David A. Largaespada(University of Minnesota), Timothy K. Starr(University of Minnesota), Susan R. Ross(University of Illinois Chicago), Reuben S. Harris(University of Minnesota)
The Journal of Experimental Medicine
July 23, 2020
Cited by 153Open Access
Full Text

Abstract

The APOBEC3 family of antiviral DNA cytosine deaminases is implicated as the second largest source of mutation in cancer. This mutational process may be a causal driver or inconsequential passenger to the overall tumor phenotype. We show that human APOBEC3A expression in murine colon and liver tissues increases tumorigenesis. All other APOBEC3 family members, including APOBEC3B, fail to promote liver tumor formation. Tumor DNA sequences from APOBEC3A-expressing animals display hallmark APOBEC signature mutations in TCA/T motifs. Bioinformatic comparisons of the observed APOBEC3A mutation signature in murine tumors, previously reported APOBEC3A and APOBEC3B mutation signatures in yeast, and reanalyzed APOBEC mutation signatures in human tumor datasets support cause-and-effect relationships for APOBEC3A-catalyzed deamination and mutagenesis in driving multiple human cancers.


Related Papers

No related papers found

Powered by citation graph analysis